UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/781,043	02/17/2004	William H. Fleming	6122-67949-01	8393
	7590 06/14/200 SPARKMAN, LLP	7	EXAMINER	
121 SW SALM		·	STEPHENS, JACQUELINE F	
SUITE 1600 PORTLAND, OR 97204			ART UNIT	PAPER NUMBER
			3761	
			¢	
	•		MAIL DATE	DELIVERY MODE
			06/14/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/781,043	FLEMING, WILLIAM H.		
Office Action Summary	Examiner	Art Unit		
	Jacqueline F. Stephens	3761		
The MAILING DATE of this communication app Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirr vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. sely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
1) Responsive to communication(s) filed on <u>2/13/07</u> .				
2a) ☐ This action is FINAL . 2b) ☑ This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims				
4) ☐ Claim(s) 1-52 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-52 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/o	vn from consideration.			
Application Papers				
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the prio application from the International Burear * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage		
Attachment(s)				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:			
S. Patent and Trademark Office				

DETAILED ACTION

Allowable Subject Matter

1. The indicated allowability of claims 44-48 is withdrawn in view of the newly discovered reference(s) to Cox USPN 5695484. Rejections based on the newly cited reference(s) follow.

Response to Arguments

2. Applicant's arguments filed 2/13/07have been fully considered but they are moot in view of the new rejection.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 4. Claims 1-43 and 49-52 are rejected under 35 U.S.C. 102(b) as being anticipated by Cox USPN 5695484.

As to claims 1, 2, 10-12, 18, 20, 21, 24, 25, 49, and 50, Cox discloses a method for absorbing leakage from an anus of a subject, comprising positioning an intergluteal absorbent pad external to the subject's anal orifice such that the pad is retained

Application/Control Number: 10/781,043

Art Unit: 3761

between the buttocks, so that discharge from the anus is absorbed by the absorbent material of the pad (col. 1, lines 40-42; col. 2, lines 15-17). Figure 4 shows the pad has a minor portion 22 superimposed on a major portion 16, which are both curvilinear in cross-section.

As to claim 3, the absorbent material is a highly absorbent swellable material (col. 2, lines 14-18).

As to claims 5, 6, 13-15, 26-28, the pad has a minor portion 22 and a major portion 16 as claimed. Cox discloses the minor portion is positioned against the subject's anus (col. lines 46-50).

As to claims 7, 19, 51, and 52, Cox discloses the pad includes an agent for absorbing odors (col. 2, lines 18-22; col. 5, lines 21-30; col. 6, lines 59-61).

As to claims 8, 9, 22, and 23, Cox discloses the pad carries a therapeutically effective amount of a medicinal agent for anal delivery, where it is reasonable to conclude a subject wearing such a pad is in need of the medicinal agent (col. 2, lines 7-19).

As to claims 31, 32, and 34-41, see Figures 1-8. Cox additionally discloses the shape can be modified to achieve maximum incontinence control (col. 6, lines 23-26).

Art Unit: 3761

As to claim 33, Cox discloses an adhesive attachment, but the pad is held without attachment to a supporting garment.

As to claims 42 and 43, Cox discloses the pad carries a therapeutically effective amount of a medicinal agent for anal delivery, where it is reasonable to conclude a subject wearing such a pad is in need of the medicinal agent (col. 2, lines 7-19).

Claim Rejections - 35 USC § 103

- 5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. Claims 44-48 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cox. Cox discloses the present invention substantially as claimed. Cox discloses a method for absorbing leakage from an anus of a subject comprising positioning an intergluteal absorbent pad external to the subject's anal orifice such that the pad is retained between the buttocks, so that discharge from the anus is absorbed by the absorbent material of the pad (col. 1, lines 40-42; col. 2, lines 15-17). Cox discloses a cavity 30 in the pad. However, Cox discloses an odor-absorbing agent present in the cavity rather than a medicinal agent in the cavity. Cox discloses the use of medicinal

Art Unit: 3761

agents in various layers in the pad (col. 2, lines 7-21). It would have been an obvious design choice to one having ordinary skill in the art to incorporate a medicinal agent in the cavity since Cox teaches the general conditions of a medicinal agent in the pad layers as well as an odor-absorbing agent in the cavity.

7. Claims 16, 17, 29, and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cox USPN 5695484 in view of Okuda et al. USPN 4920045.

Cox does not disclose the step of performing a diagnostic test on the fecal material.

Okuda discloses detection of occult blood in feces for the purpose of early finding an abnormality such as cancer or ulcer in digestion organs at an early stage (col. 4, lines 4-14). It would have been obvious to one having ordinary skill in the art to provide the method of absorbing leakage from an anus as taught in Cox with the step of diagnostic testing of the fecal material for the benefits disclosed in Okuda.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jacqueline F. Stephens whose telephone number is (571) 272-4937. The examiner can normally be reached on Monday-Friday 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tanya Zalukaeva can be reached on (571) 272-1115. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/781,043 Page 6

Art Unit: 3761

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jacqueline F Stephens

Primary Examiner
Art Unit 3761

..

May 29, 2007